Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048930 | 0.80 | ALDH1A1 (0.57) | MEN1KMT2ACYP1A2HTTMAPT | |
| SCHEMBL5390679 | 0.80 | MAPT (0.47) | MEN1KMT2ACYP1A2HTTFGFR1 | |
| SCHEMBL17743745 | 0.80 | MEN1 (0.45) | MEN1KMT2ACYP1A2HTTFGFR1 | |
| SCHEMBL9402020 | 0.80 | KMT2A (0.45) | MEN1KMT2ACYP1A2HTTMAPT | |
| SCHEMBL3750875 | 0.78 | ALDH1A1 (0.43) | MEN1KMT2ACYP1A2HTTFGFR1 | |
| SCHEMBL3746738 | 0.76 | PDE4A (0.46) | MEN1KMT2ACYP1A2HTTMAPT | |
| SCHEMBL9615636 | 0.76 | KMT2A (0.48) | MEN1KMT2ACYP1A2HTTMAPT | |
| SCHEMBL5375483 | 0.76 | NR1I2 (0.44) | MEN1KMT2ACYP1A2HTTMAPT | |
| SCHEMBL17743800 | 0.75 | SMN1; SMN2 (0.55) | MEN1KMT2ACYP1A2HTTFGFR1 | |
| SCHEMBL10396019 | 0.75 | MEN1 (0.57) | MEN1KMT2ACYP1A2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045753-A1 | New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045753-A1 | New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | MYADM, PIR, ACMSD | MEN1 1176/4885KMT2A 1806/4885CYP1A2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.